A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine.

Trial Profile

A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Atazanavir (Primary) ; Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms BATAR
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top